RENXF · Renalytix plc · Share Buybacks
$0.07
At close · Oct 8
Return incl. dividend (before tax)
Going-concern doubt
— flagged Nov 19, 2024
Substantial doubt about the company's ability to continue as a going concern.
“As a result of the Company's losses and its projected cash needs, as defined in the accounting literature, substantial doubt exists about the Company's ability to continue as a going concern. While subsequent to September 30, 2024, the company has successfully raised approximately $14.9 million, net of expenses, in new equity capital and restructured the existing long-term debt recorded on the balance sheet, the Company does have a history of operating losses and it has been expensive to deliver all of the milestones to commercialize the kidneyintelX.dkd test. … As such, management has concluded that there is a going concern uncertainty. The consolidated financial statements do not include any adjustments that may result from the outcome of this going concern uncertainty.”View the 10-Q filed Nov 19, 2024
Market Cap
$48.36M
Shares
13.25M
Volume · Oct 8
13K
Avg daily vol (5 sessions)
13.1K
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
No Buyback Data
This company's XBRL filings report no share-repurchase activity yet.